- Home
- SUZ vs VTRS Comparison
SUZ vs VTRS Comparison
Compare SUZ & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUZ
- VTRS
- Stock Information
- Founded
- SUZ 1924
- VTRS 1961
- Country
- SUZ Brazil
- VTRS United States
- Employees
- SUZ N/A
- VTRS N/A
- Industry
- SUZ Paper
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- SUZ Basic Materials
- VTRS Health Care
- Exchange
- SUZ Nasdaq
- VTRS Nasdaq
- Market Cap
- SUZ N/A
- VTRS 11.0B
- IPO Year
- SUZ N/A
- VTRS N/A
- Fundamental
- Price
- SUZ $9.11
- VTRS $8.16
- Analyst Decision
- SUZ
- VTRS Hold
- Analyst Count
- SUZ 0
- VTRS 4
- Target Price
- SUZ N/A
- VTRS $10.50
- AVG Volume (30 Days)
- SUZ 1.8M
- VTRS 15.2M
- Earning Date
- SUZ 05-08-2025
- VTRS 05-08-2025
- Dividend Yield
- SUZ 2.89%
- VTRS 5.88%
- EPS Growth
- SUZ N/A
- VTRS N/A
- EPS
- SUZ N/A
- VTRS N/A
- Revenue
- SUZ $7,664,357,082.00
- VTRS $14,739,300,000.00
- Revenue This Year
- SUZ $16.57
- VTRS N/A
- Revenue Next Year
- SUZ $9.26
- VTRS $0.99
- P/E Ratio
- SUZ N/A
- VTRS N/A
- Revenue Growth
- SUZ 19.24
- VTRS N/A
- 52 Week Low
- SUZ $8.78
- VTRS $8.15
- 52 Week High
- SUZ $12.89
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- SUZ 32.06
- VTRS 24.79
- Support Level
- SUZ $9.21
- VTRS $8.55
- Resistance Level
- SUZ $9.43
- VTRS $9.35
- Average True Range (ATR)
- SUZ 0.16
- VTRS 0.27
- MACD
- SUZ -0.01
- VTRS -0.02
- Stochastic Oscillator
- SUZ 3.68
- VTRS 1.28
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.